XenoPort Issues Statement

  XenoPort Issues Statement

Business Wire

SANTA CLARA, Calif. -- October 15, 2013

XenoPort, Inc. (NASDAQ: XNPT) today issued the following statement:

“The XenoPort Board of Directors has received the letter sent today from the
Clinton Group. The XenoPort Board and management team appreciate stockholder
input regarding the company, and we will continue to review all aspects of the
company’s business. We remain focused on enhancing stockholder value and
welcome stockholder input regarding this objective.”

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets,
its first approved product in the United States, and developing a novel
fumaric acid ester product candidate, XP23829, as a potential treatment for
relapsing-remitting multiple sclerosis and/or psoriasis. REGNITE^® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort's pipeline of product candidates also includes potential
treatments for patients with spasticity related to spinal cord injury and
Parkinson's disease.

To learn more about XenoPort, please visit the company Website at
www.XenoPort.com.

HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contact:

XenoPort
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.